Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019

GBD 2019 Diseases and Injuries Collaborators

Abstract

Background: In an era of shifting global agendas and expanded emphasis on non-communicable diseases and injuries along with communicable diseases, sound evidence on trends by cause at the national level is essential. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic scientific assessment of published, publicly available, and contributed data on incidence, prevalence, and mortality for a mutually exclusive and collectively exhaustive list of diseases and injuries.

Methods: GBD estimates incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) due to 369 diseases and injuries, for two sexes, and for 204 countries and territories. Input data were extracted from censuses, household surveys, civil registration and vital statistics, disease registries, health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Cause-specific death rates and cause fractions were calculated using the Cause of Death Ensemble model and spatiotemporal Gaussian process regression. Cause-specific deaths were adjusted to match the total all-cause deaths calculated as part of the GBD population, fertility, and mortality estimates. Deaths were multiplied by standard life expectancy at each age to calculate YLLs. A Bayesian meta-regression modelling tool, DisMod-MR 2.1, was used to ensure consistency between incidence, prevalence, remission, excess mortality, and cause-specific mortality for most causes. Prevalence estimates were multiplied by disability weights for mutually exclusive sequelae of diseases and injuries to calculate YLDs. We considered results in the context of the Socio-demographic Index (SDI), a composite indicator of income per capita, years of schooling, and fertility rate in females younger than 25 years. Uncertainty intervals (UIs) were generated for every metric using the 25th and 975th ordered 1000 draw values of the posterior distribution.

Findings: Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates. After taking into account population growth and ageing, the absolute number of DALYs has remained stable. Since 2010, the pace of decline in global age-standardised DALY rates has accelerated in age groups younger than 50 years compared with the 1990-2010 time period, with the greatest annualised rate of decline occurring in the 0-9-year age group. Six infectious diseases were among the top ten causes of DALYs in children younger than 10 years in 2019: lower respiratory infections (ranked second), diarrhoeal diseases (third), malaria (fifth), meningitis (sixth), whooping cough (ninth), and sexually transmitted infections (which, in this age group, is fully accounted for by congenital syphilis; ranked tenth). In adolescents aged 10-24 years, three injury causes were among the top causes of DALYs: road injuries (ranked first), self-harm (third), and interpersonal violence (fifth). Five of the causes that were in the top ten for ages 10-24 years were also in the top ten in the 25-49-year age group: road injuries (ranked first), HIV/AIDS (second), low back pain (fourth), headache disorders (fifth), and depressive disorders (sixth). In 2019, ischaemic heart disease and stroke were the top-ranked causes of DALYs in both the 50-74-year and 75-years-and-older age groups. Since 1990, there has been a marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries. In 2019, there were 11 countries where non-communicable disease and injury YLDs constituted more than half of all disease burden. Decreases in age-standardised DALY rates have accelerated over the past decade in countries at the lower end of the SDI range, while improvements have started to stagnate or even reverse in countries with higher SDI.

Interpretation: As disability becomes an increasingly large component of disease burden and a larger component of health expenditure, greater research and development investment is needed to identify new, more effective intervention strategies. With a rapidly ageing global population, the demands on health services to deal with disabling outcomes, which increase with age, will require policy makers to anticipate these changes. The mix of universal and more geographically specific influences on health reinforces the need for regular reporting on population health in detail and by underlying cause to help decision makers to identify success stories of disease control to emulate, as well as opportunities to improve.

Funding: Bill & Melinda Gates Foundation.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Global DALYs and age-standardised DALY rates, 1990–2019 Shaded sections indicate 95% uncertainty intervals. DALY=disability-adjusted life-year.
Figure 2
Figure 2
Leading 25 Level 3 causes of global DALYs and percentage of total DALYs (1990 and 2019), and percentage change in number of DALYs and age-standardised DALY rates from 1990 to 2019 for both sexes combined for all ages (A), children younger than 10 years (B), and ages 10–24 years (C), 25–49 years (D), 50–74 years (E), and 75 years and older (F) Causes are connected by lines between time periods; solid lines are increases in rank and dashed lines are decreases. Age-related hearing loss=age-related and other hearing loss. Alzheimer's disease=Alzheimer's disease and other dementias. Atrial fibrillation=atrial fibrillation and flutter. Cirrhosis=cirrhosis and other chronic liver diseases. COPD=chronic obstructive pulmonary disease. EMBID=endocrine, metabolic, blood, and immune disorders. DALY=disability-adjusted life-year. iNTS=invasive non-typhoidal salmonella. Haemoglobinopathies=haemoglobinopathies and haemolytic anaemias. Lung cancer=tracheal, bronchus, and lung cancer. Other musculoskeletal=other musculoskeletal disorders. Other unspecified infectious=other unspecified infectious diseases. Sudden infant death=sudden infant death syndrome. STI=sexually transmitted infections excluding HIV.
Figure 2
Figure 2
Leading 25 Level 3 causes of global DALYs and percentage of total DALYs (1990 and 2019), and percentage change in number of DALYs and age-standardised DALY rates from 1990 to 2019 for both sexes combined for all ages (A), children younger than 10 years (B), and ages 10–24 years (C), 25–49 years (D), 50–74 years (E), and 75 years and older (F) Causes are connected by lines between time periods; solid lines are increases in rank and dashed lines are decreases. Age-related hearing loss=age-related and other hearing loss. Alzheimer's disease=Alzheimer's disease and other dementias. Atrial fibrillation=atrial fibrillation and flutter. Cirrhosis=cirrhosis and other chronic liver diseases. COPD=chronic obstructive pulmonary disease. EMBID=endocrine, metabolic, blood, and immune disorders. DALY=disability-adjusted life-year. iNTS=invasive non-typhoidal salmonella. Haemoglobinopathies=haemoglobinopathies and haemolytic anaemias. Lung cancer=tracheal, bronchus, and lung cancer. Other musculoskeletal=other musculoskeletal disorders. Other unspecified infectious=other unspecified infectious diseases. Sudden infant death=sudden infant death syndrome. STI=sexually transmitted infections excluding HIV.
Figure 2
Figure 2
Leading 25 Level 3 causes of global DALYs and percentage of total DALYs (1990 and 2019), and percentage change in number of DALYs and age-standardised DALY rates from 1990 to 2019 for both sexes combined for all ages (A), children younger than 10 years (B), and ages 10–24 years (C), 25–49 years (D), 50–74 years (E), and 75 years and older (F) Causes are connected by lines between time periods; solid lines are increases in rank and dashed lines are decreases. Age-related hearing loss=age-related and other hearing loss. Alzheimer's disease=Alzheimer's disease and other dementias. Atrial fibrillation=atrial fibrillation and flutter. Cirrhosis=cirrhosis and other chronic liver diseases. COPD=chronic obstructive pulmonary disease. EMBID=endocrine, metabolic, blood, and immune disorders. DALY=disability-adjusted life-year. iNTS=invasive non-typhoidal salmonella. Haemoglobinopathies=haemoglobinopathies and haemolytic anaemias. Lung cancer=tracheal, bronchus, and lung cancer. Other musculoskeletal=other musculoskeletal disorders. Other unspecified infectious=other unspecified infectious diseases. Sudden infant death=sudden infant death syndrome. STI=sexually transmitted infections excluding HIV.
Figure 3
Figure 3
Proportion of total DALYs contributed by injury and non-communicable disease YLDs, by country or territory, 2019 Proportions were rounded to the nearest whole number. DALY=disability-adjusted life-year. YLD=year lived with disability.
Figure 4
Figure 4
Annualised rate of change in age-standardised DALY rates for all causes excluding HIV/AIDS, natural disasters, and war and conflict, and SDI by country or territory, for 1990–2010 (A) and 2010–19 (B) A simple linear regression line is shown in each figure for the relationship between annualised rate of change and the average SDI value of each country and territory for each time period. AFG=Afghanistan. AGO=Angola. ARE=United Arab Emirates. BDI=Burundi. BGD=Bangladesh. BLR=Belarus. BOL=Bolivia. BTN=Bhutan. CHN=China. CIV=Côte d'Ivoire. CMR=Cameroon. COD=Democratic Republic of the Congo. DALY=disability-adjusted life-year. DMA=Dominica. DOM=Dominican Republic. ERI=Eritrea. ETH=Ethiopia. GHA=Ghana. GNB=Guinea-Bissau. GNQ=Equatorial Guinea. GTM=Guatemala. GUM=Guam. IND=India. JAM=Jamaica. KAZ=Kazakhstan. KHM=Cambodia. KOR=South Korea. KNA=Saint Kitts and Nevis. LAO=Laos. LBR=Liberia. LCA=Saint Lucia. LSO=Lesotho. MDA=Moldova. MDV=Maldives. MMR=Myanmar. MOZ=Mozambique. MRT=Mauritania. MWI=Malawi. NER=Niger. NGA=Nigeria. NPL=Nepal. NRU=Nauru. OMN=Oman. PER=Peru. RUS=Russia. RWA=Rwanda. SDN=Sudan. SGP=Singapore. SLE=Sierra Leone. SOM=Somalia. SWZ=eSwatini. TGO=Togo. TLS=Timor-Leste. TUR=Turkey. UKR=Ukraine. UZB=Uzbekistan. VCT=Saint Vincent and the Grenadines. VEN=Venezuela. YEM=Yemen. ZAF=South Africa. ZWE=Zimbabwe. SDI=Socio-demographic Index.

References

    1. Kyu HH, Abate D, Abate KH. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1859–1922.
    1. James SL, Abate D, Abate KH. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858.
    1. Roth GA, Abate D, Abate KH. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–1788.
    1. WHO Third United Nations high-level meeting on NCDs. 2018.
    1. WHO . WHO Regional Office for Europe; Copenhagen: 2016. Action plan for the prevention and control of noncommunicable diseases in the WHO European Region.
    1. Vayena E, Dzenowagis J, Brownstein JS, Sheikh A. Policy implications of big data in the health sector. Bull World Health Organ. 2018;96:66–68.
    1. United Nations General Assembly . United Nations; New York: 2018. Political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases.
    1. Stevens GA, Alkema L, Black RE. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet. 2016;388:e19–e23.
    1. WHO International Classification of Diseases (ICD) 2018.
    1. Rudd K, Johnson S, Agesa K. Global, regional, and national sepsis incidence and mortality, 1990–2017. Lancet. 2020;395:200–211.
    1. Fullman N, Yearwood J, Abay SM. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet. 2018;391:2236–2271.
    1. Afshin A, Sur PJ, Fay KA. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2019;393:1958–1972.
    1. GBD 2019 Demographics Collaborators Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1160–1203.
    1. Jones GH, Bruera E, Abdi S, Kantarjian HM. The opioid epidemic in the United States—overview, origins, and potential solutions. Obstet Gynecol Surv. 2019;74:278.
    1. Lyden J, Binswanger IA. The United States opioid epidemic. Semin Perinatol. 2019;43:123–131.
    1. National Institute on Drug Abuse Opioid overdose crisis. February, 2020.
    1. Public Health Agency of Canada Apparent opioid-related deaths in Canada. December, 2019.
    1. Soliman G, Elzalabany MS, Hassanein T, Miller FD. Mass screening for hepatitis B and C in Southern Upper Egypt. BMC Public Health. 2019;19
    1. Abdel-Razek W, Hassany M, Kabil K. The world's largest hepatitis C screening program in Egypt. 2019.
    1. Omran D, Alboraie M, Zayed RA. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol. 2018;24:4330–4340.
    1. Elgharably A, Gomaa AI, Crossey MM, Norsworthy PJ, Waked I, Taylor-Robinson SD. Hepatitis C in Egypt—past, present, and future. Int J Gen Med. 2016;10:1–6.
    1. Rao MR, Naficy AB, Darwish MA. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis. 2002;2:29.
    1. Plotzker RE, Murphy RD, Stoltey JE. Congenital syphilis prevention: strategies, evidence, and future directions. Sex Transm Dis. 2018;45(suppl 1):S29–S37.
    1. Korenromp EL, Rowley J, Alonso M. Global burden of maternal and congenital syphilis and associated adverse birth outcomes—estimates for 2016 and progress since 2012. PLoS One. 2019;14
    1. Vollset S, Goren E, Yuan C-W. Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study. Lancet. 2020;396:1285–1306.
    1. Ferrari AJ, Norman RE, Freedman G. The burden attributable to mental and substance use disorders as risk factors for suicide: findings from the Global Burden of Disease Study 2010. PLoS One. 2014;9
    1. Sha F, Chang Q, Law YW, Hong Q, Yip PSF. Suicide rates in China, 2004–2014: comparing data from two sample-based mortality surveillance systems. BMC Public Health. 2018;18:239.
    1. Sha F, Yip PSF, Law YW. Decomposing change in China's suicide rate, 1990–2010: ageing and urbanisation. Inj Prev. 2017;23:40–45.
    1. Mew EJ, Padmanathan P, Konradsen F. The global burden of fatal self-poisoning with pesticides 2006–15: systematic review. J Affect Disord. 2017;219:93–104.
    1. Hogan MF, Grumet JG. Suicide prevention: an emerging priority for health care. Health Aff (Millwood) 2016;35:1084–1090.
    1. WHO. UNAIDS . World Health Organization; Geneva: 2006. Progress on global access to HIV antiretroviral therapy.
    1. Stover J, Bollinger L, Izazola JA, Loures L, DeLay P, Ghys PD. What is required to end the AIDS epidemic as a public health threat by 2030? The cost and impact of the fast-track approach. PLoS One. 2016;11
    1. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17:104.
    1. Lopez AD, Adair T. Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. Int J Epidemiol. 2019;48:1815–1823.
    1. Leong DP, Joseph PG, McKee M. Reducing the global burden of cardiovascular disease, part 2. Circ Res. 2017;121:695–710.
    1. GBD 2019 Risk Factors Collaborators Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223–1249.
    1. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83.
    1. Engelen SE, van der Graaf Y, Stam-Slob MC. Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes. Int J Cardiol. 2017;248:301–307.
    1. Harries AD, Lin Y, Kumar AMV. What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030? F1000Res. 2018;7 F1000 Faculty Rev-1011.
    1. Suthar AB, Zachariah R, Harries AD. Ending tuberculosis by 2030: can we do it? Int J Tuberc Lung Dis. 2016;20:1148–1154.
    1. WHO . World Health Organization; Geneva: 2019. Global tuberculosis report 2019.
    1. Ene-Iordache B, Perico N, Bikbov B. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016;4:e307–e319.
    1. Stanifer JW, Isenburg MV, Chertow GM, Anand S. Chronic kidney disease care models in low- and middle-income countries: a systematic review. BMJ Glob Health. 2018;3
    1. Rehm J, Crépault J-F, Hasan OSM, Lachenmeier DW, Room R, Sornpaisarn B. Regulatory policies for alcohol, other psychoactive substances and addictive behaviours: the role of level of use and potency. A systematic review. Int J Environ Res Public Health. 2019;16
    1. Lin FR. Time for a top-down approach to hearing aid affordability and accessibility. Am J Public Health. 2018;108:166–168.
    1. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (NY) 2018;4:195–214.
    1. Larsson SC, Markus HS. Does treating vascular risk factors prevent dementia and Alzheimer's disease? A systematic review and meta-analysis. J Alzheimers Dis. 2018;64:657–668.
    1. Yaffe K. Modifiable risk factors and prevention of dementia: what is the latest evidence? JAMA Intern Med. 2018;178:281–282.
    1. Brasure M, Desai P, Davila H. Physical activity interventions in preventing cognitive decline and Alzheimer-type dementia: a systematic review. Ann Intern Med. 2018;168:30.
    1. Seppala LJ, van de Glind EMM, Daams JG. Fall-risk-increasing drugs: a systematic review and meta-analysis: III. Others. J Am Med Dir Assoc. 2018;19:372.e1–372.e8.
    1. Xu T, Clemson L, O'Loughlin K, Lannin NA, Dean C, Koh G. Risk factors for falls in community stroke survivors: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2018;99:563. 73.e5.
    1. Lan X, Li H, Wang Z, Chen Y. Frailty as a predictor of future falls in hospitalized patients: A systematic review and meta-analysis. Geriatr Nur. 2019 doi: 10.1016/j.gerinurse.2019.01.004. published online Feb 11.
    1. Cheng P, Tan L, Ning P. Comparative effectiveness of published interventions for elderly fall prevention: a systematic review and network meta-analysis. Int J Environ Res Public Health. 2018;15:498.
    1. WHO Noncommunicable diseases. June 1, 2018.
    1. Nugent R, Bertram MY, Jan S. Investing in non-communicable disease prevention and management to advance the Sustainable Development Goals. Lancet. 2018;391:2029–2035.
    1. Cottingham MD, Kalbaugh CA, Fisher JA. Tracking the pharmaceutical pipeline: clinical trials and global disease burden. Clin Transl Sci. 2014;7:297–299.
    1. Fisher JA, Cottingham MD, Kalbaugh CA. Peering into the pharmaceutical “pipeline”: investigational drugs, clinical trials, and industry priorities. Soc Sci Med. 2015;131:322–330.
    1. Long G. Analysis Group; Boston, MA: 2017. The biopharmaceutical pipeline: innovative therapies in clinical development.
    1. Singh GK, Siahpush M, Azuine RE, Williams SD. Increasing area deprivation and socioeconomic inequalities in heart disease, stroke, and cardiovascular disease mortality among working age populations, United States, 1969–2011. Int J MCH AIDS. 2015;3:119–133.
Uncited Reference
    1. Schultze-Kraft M, Chinchilla FA, Moriconi M. New perspectives on crime, violence and insecurity in Latin America. Crime Law Soc Change. 2018;69:465–473.

Source: PubMed

3
Abonner